These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. Na IK; Buckland M; Agostini C; Edgar JDM; Friman V; Michallet M; Sánchez-Ramón S; Scheibenbogen C; Quinti I Eur J Haematol; 2019 Jun; 102(6):447-456. PubMed ID: 30801785 [TBL] [Abstract][Full Text] [Related]
4. Secondary Immune Deficiency and Primary Immune Deficiency Crossovers: Hematological Malignancies and Autoimmune Diseases. Ballow M; Sánchez-Ramón S; Walter JE Front Immunol; 2022; 13():928062. PubMed ID: 35924244 [TBL] [Abstract][Full Text] [Related]
5. Primary immunodeficiency disorders in children: prompt diagnosis can lead to lifesaving treatment. Champi C J Pediatr Health Care; 2002; 16(1):16-21. PubMed ID: 11802116 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Effectiveness of the 6 Warning Signs of the European Society for Immunodeficiencies for Primary Immunodeficiencies in Older Adults. Yildiz E; Çölkesen F; Evcen R; Sadi Aykan F; Kılınç M; Arslan S Int Arch Allergy Immunol; 2024; 185(4):402-410. PubMed ID: 38219730 [TBL] [Abstract][Full Text] [Related]
7. Primary immunodeficiency and autoimmunity: A comprehensive review. Amaya-Uribe L; Rojas M; Azizi G; Anaya JM; Gershwin ME J Autoimmun; 2019 May; 99():52-72. PubMed ID: 30795880 [TBL] [Abstract][Full Text] [Related]
11. [Patient support for primary immunodeficiency with hypogammaglobulinemia and intravenous immunoglobulin substitution: result of a national survey]. Suarez F; Puget S; Beaudet R; Goulamhoussen N; Hermine O Presse Med; 2010 Mar; 39(3):e45-51. PubMed ID: 20122813 [TBL] [Abstract][Full Text] [Related]
12. Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. Seidel MG Blood; 2014 Oct; 124(15):2337-44. PubMed ID: 25163701 [TBL] [Abstract][Full Text] [Related]
14. Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies. Blau IW; Conlon N; Petermann R; Nikolov N; Plesner T Expert Rev Clin Immunol; 2016 Jul; 12(7):705-11. PubMed ID: 27156362 [TBL] [Abstract][Full Text] [Related]
15. The case for a national service for primary immune deficiency disorders in New Zealand. Ameratunga R; Steele R; Jordan A; Preece K; Barker R; Brewerton M; Lindsay K; Sinclair J; Storey P; Woon ST N Z Med J; 2016 Jun; 129(1436):75-90. PubMed ID: 27355232 [TBL] [Abstract][Full Text] [Related]
16. How effective are the 6 European Society of Immunodeficiency warning signs for primary immunodeficiency disease? Arslan S; Ucar R; Caliskaner AZ; Reisli I; Guner SN; Sayar EH; Baloglu I Ann Allergy Asthma Immunol; 2016 Feb; 116(2):151-155.e1. PubMed ID: 26815708 [TBL] [Abstract][Full Text] [Related]
17. Management of primary antibody deficiency by consultant immunologists in the United Kingdom: a paradigm for other rare diseases. Spickett GP; Askew T; Chapel HM Qual Health Care; 1995 Dec; 4(4):263-8. PubMed ID: 10156396 [TBL] [Abstract][Full Text] [Related]
18. Differing Performance of the Warning Signs for Immunodeficiency in the Diagnosis of Pediatric Versus Adult Patients in a Two-Center Tertiary Referral Population. Bjelac JA; Yonkof JR; Fernandez J J Clin Immunol; 2019 Jan; 39(1):90-98. PubMed ID: 30610441 [TBL] [Abstract][Full Text] [Related]
19. Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology. Shah N; Mustafa SS; Vinh DC Crit Rev Oncol Hematol; 2023 Jan; 181():103896. PubMed ID: 36528276 [TBL] [Abstract][Full Text] [Related]